Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Procarbazine hypersensitivity manifested as a fixed drug eruption.

J K Giguere1, D M Douglas, G P Lupton

  • 1Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307.

Medical and Pediatric Oncology
|January 1, 1988
PubMed
Summary

A previously unknown hypersensitivity reaction to procarbazine, presenting as a nonpigmented fixed drug eruption, was identified. Drug rechallenge confirmed the association, highlighting a rare procarbazine side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2013 SYR Accepted Poster Abstracts.

International journal of yoga therapy·2013
Same author

Rapid Death in Bile Peritonitis.

British medical journal·2010
Same author

Effect of Peritoneal Irritation on the Activity of the Intestine.

British medical journal·2010
Same author

Strangulated Hernia: A Consideration of Some Factors affecting the Mortality.

British medical journal·2010
Same author

Irreparable Vesico-vaginal Fistula in Iraq.

British medical journal·2010
Same author

Cystic adventitial disease of the popliteal artery.

British medical journal·2010

Area of Science:

  • Pharmacology
  • Dermatology
  • Toxicology

Background:

  • Procarbazine is an antineoplastic agent used in chemotherapy.
  • Hypersensitivity reactions to medications can manifest in various ways.
  • Fixed drug eruptions are a specific type of cutaneous adverse drug reaction.

Observation:

  • A case report details a patient experiencing a nonpigmented fixed drug eruption.
  • Initial skin testing did not definitively link the eruption to procarbazine.
  • Drug rechallenge was crucial in establishing the causal relationship.

Findings:

  • A novel form of procarbazine hypersensitivity was identified.
  • The reaction presented as a nonpigmented fixed drug eruption.
  • Confirmation of procarbazine as the causative agent required drug rechallenge.

Related Experiment Videos

Implications:

  • This case expands the known spectrum of procarbazine-induced hypersensitivity.
  • It underscores the diagnostic value of drug rechallenge in fixed drug eruptions.
  • Understanding these reactions is vital for patient safety in chemotherapy.